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Edited by Frances ShannonAbstract Repression of activation of c-Jun N-terminal kinase
(JNK) participates in the anti-apoptotic eﬀect of nuclear fac-
tor-jB (NF-jB) in TNFa-treated Ewing sarcoma cells. As oxi-
dative stress is one of the most prominent activators of JNK,
we investigated the relationship between TNFa-induced NF-jB
activation and the control of oxidative stress. Inhibition of NF-
jB activation resulted in an increase in TNFa-induced ROS pro-
duction, lipid peroxidation and protein oxidation. Those ROS
and lipid peroxides were both involved in TNFa-induced apopto-
sis, whereas only ROS elevation triggered sustained JNK activa-
tion. TNFa increased the level of two antioxidant enzymes,
thioredoxin and manganese superoxide dismutase by an NF-
jB-dependent mechanism. Inhibition of expression or activity
of these enzymes sensitized cells to TNFa-induced apoptosis,
indicating their functional role in protection from cell death.
Thus, agents that inhibit activities of these enzymes may prove
helpful in the treatment of Ewing tumors.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ewing tumor1. Introduction
Ewing sarcomas are the second most common bone tumors
in children and adolescents [1–3]. We have previously demon-
strated that activation of the transcription factor nuclear fac-
tor-jB (NF-jB) protects Ewing sarcoma cells from death
induced by several apoptotic stimuli, thus suggesting that
inhibition of this factor may be a way of increasing chemo-
therapy eﬃcacy [4]. This protection was shown to be at least
partly mediated through NF-jB-induced repression of c-Jun
N-terminal kinase (JNK) activation [5]. However, the mecha-
nisms of these eﬀects are still incompletely understood, inAbbreviations: BNP, N-t-butyl-a-phenyl-nitrone; DETC, diethyldithio-
carbamic acid; JNK, c-Jun N-terminal kinase; IjB, inhibitor jB;
MnSOD, manganese superoxide dismutase; MnTBAP, manga-
nese(III)tetrakis(4-benzoic acid) and porphyrin; NF-jB, nuclear fac-
tor-jB; PARP, poly(ADP-ribose) polymerase; ROS, reactive oxygen
species; TNFa, tumor necrosis factora
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doi:10.1016/j.febslet.2004.10.082particular, the link between NF-jB activation and control
of oxidative damage-induced apoptosis in Ewing sarcoma
cells.
TNFa can induce cell killing in several cell lines through
complex signal transduction initiated by its binding to TNF
receptors (TNF-R) [6]. This binding is followed by the
recruitment of the adapter molecule FADD, which binds
pro-caspase-8, resulting in activation of caspase-8. Subse-
quently, the active form of caspase-8 triggers activation of
other caspases, e.g., caspase-3, which execute the terminal
phase of apoptosis [7]. Caspase-8 activation can also lead
to cleavage of Bid, which may initiate activation of the mit-
ochondrial death pathway by altering several mitochondrial
functions [8,9].
Depending on the cell type, it has also been shown that
TNFa signaling can lead to production of reactive oxygen
species (ROS), mainly superoxide anion O2 , hydrogen per-
oxide (H2O2), and hydroxyl radical (OH
) [10–12]. The level
of ROS produced in cells is strictly regulated by enzymatic
and non-enzymatic antioxidant eﬀectors that can either di-
rectly scavenge ROS or repair oxidative damage [13–15].
When ROS generation exceeds the cells antioxidant capacity,
oxidative damage to cellular components can occur. This sit-
uation is termed oxidative stress and can cause cell death
[13,14,16,17]. A role of ROS in TNFa-mediated death signa-
ling was suggested by the observation that antioxidants inhib-
ited the apoptotic action of this cytokine in several cell lines
[11].
TNFa can also activate the NF-jB transcription factor by
recruiting the adapter protein TRADD. Signaling through
TRADD culminates in the phosphorylation and degradation
of an NF-jB inhibitor of the IjB family, which leads to the
activation of the NF-jB transcription factor and promotes
the transcription of several anti-apoptotic genes [4,18,19].
In the present study, we questioned whether NF-jB activa-
tion modulates TNFa-induced oxidative stress in Ewing sar-
coma cells. We report that, in the absence of NF-jB
activation, TNFa induces ROS production, lipid peroxidation
and protein oxidation. We show that intracellular ROS accu-
mulation participates in TNFa-induced apoptosis and the sus-
tained JNK activation that occurs when NF-jB activation is
impaired. We also show that TNFa induces a modulation of
the expression of thioredoxin and manganese superoxide
dismutase (MnSOD) in an NF-jB dependent manner, and that
these two antioxidant enzymes are involved in the protection
of Ewing sarcoma cells from TNFa-induced apoptotic oxida-
tive stress.lished by Elsevier B.V. All rights reserved.
Fig. 1. Inhibition of NF-jB activation results in oxidative stress in
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2.1. Reagents
DL-a-Tocopherol (vitamin E), Hoechst 33258 dye, Benzon nuclease,
2-thiobarbituric acid, recombinant thioredoxin from Escherichia coli,
diethyldithiocarbamic acid (DETC), N-t-butyl-a-phenyl-nitrone
(BPN) and t-butyl hydroperoxide (t-BH) were from Sigma (St. Quentin
Fallier, France). Hydroethidium was from Molecular Probes, Inc.
(Leiden, The Netherlands). Chariot, a protein delivery reagent, was
from Active Motif (Rixensart, Belgium), manganese(III)tetrakis(4-
benzoic acid) and porphyrin (MnTBAP) were from Alexis (Illkirch,
France). Recombinant human TNFa (speciﬁc activity: 5 · 107 U/mg)
was from Bender Wien and was used at a concentration of 2000 U/ml.
2.2. Cells
EW7 cells transfected with an empty pc DNA vector (EW7pc cells)
or with the IjBa (A32/36)-encoding vector (EW7MAD cells) were pre-
viously described [4]. Cells were grown at 37 C in RPMI medium sup-
plemented with 2 mM L-glutamine and 10% fetal calf serum.
2.3. Detection of apoptosis
Condensed and fragmented nuclei were detected with Hoechst 33258
ﬂuorescent dye. A total of 500 nuclei were counted for each sample.
DNA fragmentation was quantiﬁed using a cell death detection kit
(Roche Diagnostics GmbH, Mannheim, Germany).
2.4. ROS production measurement
Dihydroethidium (HE) was used to monitor intracellular oxidative
stress. Brieﬂy, cells were collected following treatment, washed with
PBS and then loaded with 2 lM HE for 30 min at 37 C. The ﬂuores-
cence of ethidium in cells was measured with a cytoﬂuorometer.
2.5. Determination of protein oxidation and lipid peroxidation
Protein oxidation was determined using an OXYBLOT kit (Intergen
Company, Purchase, NY). Brieﬂy, whole cell extracts were analyzed
for protein oxidation by derivatization with 2,4-dinitrophenyl hydra-
zine of protein carbonyls, which were then analyzed by Western blot-
ting using anti-DNP. The lipid peroxidation end-product
malondialdehyde (MDA) was measured as previously described by
using the TBARS (thiobarbituric acid reactive substances) assay [20].
2.6. Western blot analysis
Equal protein amounts of whole cell extract were analyzed by Wes-
tern blotting as previously described [21]. Antibodies against the fol-
lowing proteins were used: MnSOD (Upstate Biotechnology, Lake
Placid, NY), actin (ICN Biomedicals, Inc., Costa Mesa, CA), thiore-
doxin, catalase (Sigma, St Quentin Fallier, France), PARP (Alexis, Ill-
kirch, France), heme oxygenase 1 (BD Biosciences, Erembodegem,
Belgium), phospho-JNK (New England Biolabs, Beverly, MA, USA)
and JNK-1 (Santacruz Biotechnology Inc., Ca, USA).
2.7. Transfections
Antisense phosphorothioate oligonucleotide against thioredoxin 5 0-
AGTCTTGCTCTCTCGATCTGCTTCACCAT-3 0 and the control
sense oligonucleotide 5 0-ATGGTGAAGCAGATCGAGAGAAAG-
ACT-3 0 were used [22]. Transfection was carried out with 10 lM of
each oligonucleotide by using lipofectamine 2000. Cells were then incu-
bated for 24 h at 37 C before addition of TNFa. Recombinant thiore-
doxin (10 lg) was delivered to cells 5 h before TNFa treatment, by
using the Chariot kit. The percentages of apoptotic cells and protein
expression were determined 16 h after TNFa treatment by staining
with Hoechst 33258 dye and Western blot analysis, respectively.TNFa-treated Ewing sarcoma cells. EW7pc cells and EW7MAD cells
were treated with TNFa for the indicated times. (A) Cells were then
labeled with 2 lM hydroethidium for 30 min at 37 C. Ethidium
ﬂuorescence was analyzed by FACS. One representative experiment
out of three is shown. (B) Whole cell extracts were analyzed for protein
oxidation with the Oxyblot kit. (C) EW7pc cells and EW7MAD cells
were incubated with or without 50 lM vitamin E (Vit E) for 16 h and
then treated with 2000 U/ml TNFa for 16 h. The lipid peroxidation
end-products were measured and the results are expressed as pmol of
malondialdehyde (MDA) equivalents per lg of protein. Results
represent means ± S.E.M. of three independent experiments.3. Results
3.1. TNFa-induced oxidative stress in Ewing sarcoma cells
occurs only in the absence of NF-jB activation
To investigate the relationship between the status of NF-jB
activation and ROS production in Ewing sarcoma cells, we
compared ROS production of TNFa-treated EW7MAD cells,in which NF-jB activation is inhibited by stable expression of
a super repressor form of IjBa, IjBa (A32/36), with that of
TNFa-treated control cells (EW7pc cells) [4]. Intracellular
ROS production was measured by using the non-ﬂuorescent
hydroethidium compound which, when oxidized, yields ﬂuo-
rescent ethidium. As shown in Fig. 1A, TNFa treatment of
EW7MAD cells resulted in an increase in ethidium ﬂuores-
cence intensity as compared to control cells. This eﬀect was
detectable after 8 h of treatment and was markedly increased
after 16 h, indicating that TNFa-induced intracellular accumu-
lation of ROS. Inversely, we found that treatment of EW7pc
cells with TNFa did not result in the accumulation of ROS
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tion in TNFa-treated EW7MAD cells allows intracellular
ROS production.
Excess intracellular ROS production and/or impairment of
the antioxidant defense system may result in oxidative damage
leading to cell death [14]. We therefore investigated whether
TNFa induced such damage in EW7MAD cells. As shown
in Fig. 1B, TNFa markedly increased the level of oxidized pro-
teins in EW7MAD cells as compared to EW7pc cells. As exces-
sive ROS production in cells may induce damage of cellular
lipids, we determined the level of lipid peroxidation end-
product, malondialdehyde, in EW7pc cells and EW7MAD
after treatment with TNFa. As shown in Fig. 1C, TNFa in-
duced a signiﬁcantly greater increase in lipid peroxidation in
EW7MAD as compared to EW7pc cells. As expected, vitamin
E, a known lipid peroxidation chain-breaking antioxidant,
completely inhibited lipid peroxidation induced by TNFa.
3.2. ROS scavengers inhibit both TNFa-induced apoptosis and
activation of JNK and caspase-3 in EW7MAD cells
In order to determine the role of oxidative stress in apopto-
sis, EW7MAD cells were pre-treated with the ROS scavenger,
BPN or vitamin E before addition of TNFa and apoptosis was
evaluated by Hoechst staining. We found that both treatment
with BPN and vitamin E reduced TNFa-induced cell death in
EW7MAD cells, indicating the participation of ROS and lipid
peroxidation in TNFa-induced apoptosis (Fig. 2A). As we
have previously shown that TNFa-induced apoptosis in EW7-
MAD cells requires both sustained activation of JNK and cas-
pase 3 activation [4,5], we examined the eﬀects of BPN and
vitamin E on these apoptotic events. As shown in Fig. 2B, pre-
treatment of EW7MAD cells with BPN completely abrogated
the sustained activation of JNK triggered by TNFa when NF-
jB activation was impaired, while vitamin E had no eﬀect.
These results show that ROS production, but not lipid perox-
idation is involved in the prolongation of JNK activation. We
also examined the eﬀect of antioxidant supplementation onFig. 2. Antioxidants inhibit both TNFa-induced apoptosis and
activation of JNK and caspase-3. EW7MAD cells were ﬁrst treated
with either 50 lM N-t-butyl-a phenyl-nitone (BPN) for 2 h or with 50
lM vitamin E (Vit E) for 16 h prior to treatment with TNFa for 16 h.
(A) The percentage of apoptotic cells was determined by staining with
Hoechst. (B, C) Cellular extracts were prepared and analyzed by
Western blot using antibodies directed against either phosphoJNK
(PPJNK), anti-JNK-1 (B) or PARP (C). One representative experiment
out of two is shown.TNFa-induced caspase-3 activation which was assessed by
the appearance of cleavage products of PARP, a well-known
substrate of this caspase. As shown in Fig. 2C, addition of
BPN or vitamin E reduced TNFa-induced PARP cleavage in
EW7MAD cells. These results suggest that TNFa-induced
ROS production and lipid peroxidation are both involved in
caspase-3 activation, whereas sustained JNK activation is only
mediated by the elevation of ROS concentration.
3.3. Treatment with TNFa results in increased expression of
antioxidant enzymes in EW7pc cells as compared to
EW7MAD cells
The redox status of cells is regulated by the intracellular
antioxidant defense system [15]. Our results showing that
TNFa induced production of ROS in EW7MAD cells but
not in EW7pc cells suggest an impairment of the antioxidant
defense system in EW7MAD cells in comparison to EW7pc
cells. The level of expression of antioxidant enzymes was there-
fore compared in these two cell types upon treatment with
TNFa. Several distinct cellular antioxidant enzymes were
examined: manganese superoxide dismutase, a mitochondrial
antioxidant which scavenges superoxide anion, thioredoxin
which by its oxido-reductase activity scavenges ROS andFig. 3. Comparison of the antioxidant enzyme status in Ewing sarcoma
cells treatedwithTNFa in the presence andabsenceof a repressor ofNF-
jB activation. (A) EW7pc cells and EW7MAD cells were treated with
TNFa for the indicated times before cell lysis. Equal protein amounts of
whole cell extract were analyzed by Western blotting using antibodies
directed against thioredoxin, MnSOD, heme oxygenase-1, and catalase.
One representative experiment out of three is shown. Bands corre-
sponding to thioredoxin (B) andMnSOD (C)were quantiﬁed usingNIH
Image software and were normalized to the actin. Values represent
means ± S.E.M. of three independent experiments.
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which neutralizes hydrogen peroxide production by its conver-
sion to water [15]. Heme oxygenase-1 was also examined as it is
known to act as an antioxidant by leading to the formation of
bilirubin, which possesses ROS scavenger properties [23]. As
shown in Fig. 3A, TNFa upregulated both thioredoxin and
manganese superoxide dismutase expression in EW7pc cells
but not in EW7MAD cells. Expression of catalase and heme
oxygenase-1 remained unchanged in both cells after treatment
with TNFa.
3.4. Thioredoxin and manganese superoxide dismutase are both
involved in protection against apoptosis induced by TNFa in
EW7pc
The higher level of expression of thioredoxin and MnSOD in
response to TNFa in EW7pc cells compared to that observed
in EW7MAD cells suggests a role of these antioxidant enzymes
in protection against TNFa-induced apoptosis in EW7pc cells.
To test this hypothesis, we examined, on the one hand, the eﬀect
of antioxidant supplementation on TNFa-induced apoptosis in
EW7MAD and, on the other hand, the eﬀect of inhibition of
thioredoxin and MnSOD activities on the sensitivity of EW7pcFig. 4. Thioredoxin and MnSOD are both involved in protection
against apoptosis induced by TNFa in EW7pc cells. (A) EW7MAD
cells and (B) EW7pc cells were ﬁrst incubated for 2 h with MnTBAP
(100 lM) and DETC (5 mM), respectively, and then treated for 16 h
with TNFa before evaluation of apoptosis by Hoechst staining. (C)
Thioredoxin recombinant proteins were delivered to EW7MAD cells
by using the Chariot kit 5 h before TNFa treatment. (D) The sense and
antisense thioredoxin oligonucleotides were introduced into EW7pc
cells by using lipofectamine 2000, 24 h before the beginning of TNFa
treatment. The percentages of apoptotic cells and thioredoxin protein
expression were determined by staining with Hoechst staining and
Western blot analysis, respectively, after 16 h of TNF treatment. C:
untreated, AS: antisense treated, S: sense treated, CL: lipofectamine
alone treated. Values represent means ± S.E.M. of three independent
experiments.cells to TNFa-induced cell death. As shown in Fig. 4A, addi-
tion of the MnTBAP compound that mimics MnSOD activity
partially protected against TNFa-induced cell death in EW7-
MAD cells, as evaluated by Hoechst staining. In contrast, in
EW7pc cells inhibition of superoxide dismutase activity by
DETC by itself induced cell death, which was enhanced in
the presence of TNFa treatment (Fig. 4B). Similar experiments
have been done to determine the role of thioredoxin in the con-
trol of apoptosis. As shown in Fig. 4C, pretreatment of EW7-
MAD cells with recombinant thioredoxin partially inhibited
TNFa-induced apoptosis. On the other hand, inhibition of thi-
oredoxin expression in EW7pc by an antisense oligonucleotide
sensitized these cells to TNFa treatment (Fig. 4D). These re-
sults demonstrate the functional role of both thioredoxin and
MnSOD in protection against apoptosis in EW7pc cells.4. Discussion
In the present study, we provide evidence that NF-jB activa-
tion prevents apoptotic oxidative stress induced by TNFa in
Ewing sarcoma cells. This interpretation is based on results
showing that (1) TNFa promotes accumulation of ROS and
induces protein and lipid oxidation only in cells in which
NF-jB activation is impaired. (2) In the latter cells, ROS scav-
engers inhibit TNFa-induced apoptosis.
Cellular antioxidants can control the redox status of cells in
response to an oxidant injury [13,14]. Depending on cell type,
NF-jB activation can regulate the expression of several anti-
oxidant enzymes that may be involved in protection against cell
injury [24–27]. The role of thioredoxin in the control of oxida-
tive stress induced by TNFa has also been pointed out [28], but
there are no data concerning the involvement of NF-jB activa-
tion in the regulation of its expression. In the present study, we
show for the ﬁrst time that, in Ewing sarcoma cells, NF-
jB-dependent thioredoxin expression is involved in protection
against TNFa-induced apoptosis. The eﬀective role of thiore-
doxin in the protection against TNFa-induced apoptosis was
demonstrated by experiments showing that speciﬁc inhibition
of thioredoxin expression sensitized Ewing sarcoma cells to
TNFa-induced apoptosis. Furthermore, the addition of rec-
ombinant thioredoxin inhibited apoptosis of Ewing sarcoma
cells in which NF-jB activation was impaired. In agreement
with our results, it has been shown that cancer cell lines with
elevated expression of thioredoxin are resistant to a variety of
apoptosis-inducing agents, including ROS [29,30]. This protec-
tive eﬀect of thioredoxin is assumed to be the result of its anti-
oxidant function [15,31]. We found that NF-jB activation also
increased the expression level of MnSOD in TNFa-treated Ew-
ing sarcoma cells. In accordance with our results, it has been
shown that overexpression of MnSOD prevents apoptosis in-
duced by several oxidative stress inducers, including TNFa
[32–34]. In contrast, upregulation of MnSOD can induce apop-
tosis in some other model systems [35]. Moreover, it has also
been reported that upregulation of MnSOD by the c-Rel tran-
scription factor ﬁrst induces resistance to the apoptotic burst of
O2 produced by TNFa and later increases H2O2 accumula-
tion, which results in apoptosis of HeLa cells [15,36]. These dif-
ferent results may be explained by the fact that MnSOD is an
enzyme which catalyzes the dismutation of superoxide anion
to hydrogen peroxide, which still has to be neutralized by sev-
eral antioxidant peroxidases [37]. However, if the latter antioxi-
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cells and may in turn induce oxidative stress. Thus, the balance
between MnSOD and peroxidase activities in cells could deter-
mine the anti- or pro-apoptotic eﬀect of MnSOD upregulation
in cells. Our results suggest that in Ewing sarcoma cells, thiore-
doxin may contribute to the neutralization of the H2O2 pro-
duced by TNFa-enhanced MnSOD activity.
We found that impairment of NF-jB activity resulted in
protein and lipid oxidation in TNFa-treated Ewing sarcoma
cells. Thioredoxin is a well-known example of a protein that
is negatively regulated in its function upon oxidation. Oxida-
tion of thioredoxin leads to the dissociation of ASK-1 from
thioredoxin and to its activation. Subsequently, the activated
form of ASK-1 can trigger JNK activation [38–40]. Although
both pro- and anti-apoptotic eﬀects of JNK have been re-
ported [41], activation of this MAP kinase has been clearly
shown to induce apoptosis in Ewing sarcoma cells [5,21]. In
these cells, induction of apoptosis by TNFa required a sus-
tained activation of JNK which occurred only in the absence
of NF-jB activation [5]. In the present study, we identiﬁed
TNFa-induced ROS production as the cause of the sustained
activation of JNK observed in EW7 cells carrying a repressor
of NF-jB activation as compared to control cells. Thus, the
modulation of the JNK pathway by ROS is one of the mech-
anisms by which TNFa-induces apoptosis in these cells. In
accordance with our results, a recent report showed that
NF-jB inhibits TNFa-induced accumulation of ROS, which
mediates prolonged MAPK activation and necrotic cell death
in murine embryonic ﬁbroblasts (MEFs) [42]. Also, Chen
et al. [43] demonstrated that the increased accumulation of
ROS is responsible for the prolonged JNK activation in
arsenic-stimulated IKKb/ MEFs.
We also found that TNFa induced lipid peroxidation in cells
expressing the inhibitor of NF-jB activation. Addition of vita-
min E, a well-known inhibitor of lipid peroxidation, protected
these cells against TNFa-induced apoptosis and caspase-3 acti-
vation without any eﬀect on JNK activation, indicating that li-
pid peroxidation triggered a death signal downstream of JNK
activation. In accordance with these results, it has been shown
that agents that induce lipid peroxidation activate cell death in
several cell lines [44]. One of the mechanisms that has been
proposed to explain this eﬀect is the dissociation of cyto-
chrome c from mitochondria upon peroxidation of the mitoch-
ondrial membrane [45].
In summary, we have identiﬁed mechanisms by which NF-
jB controls intracellular ROS production and protein or lipid
oxidation induced by TNFa in Ewing sarcoma cells. Our ﬁnd-
ings also suggest that agents that decrease thioredoxin and
MnSOD activities might be beneﬁcial adjuvants in the treat-
ment of Ewing tumors.
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